Education
About Us
Working with TipRanks
Follow Us
Glaukos Corp. (GKOS)
:GKOS
GKOS Stock Chart & Stats
$108.72
$1.50(0.96%)
At close: 4:00 PM EST
$108.72
$1.50(0.96%)
Day’s Range― - ―
52-Week Range$73.16 - $163.71
Previous CloseN/A
Volume137.72K
Average Volume (3M)1.17M
Market Cap
$6.14B
Enterprise Value$4.51B
Total Cash (Recent Filing)$273.71M
Total Debt (Recent Filing)$104.31M
Price to Earnings (P/E)―
Beta1.17
Next Earnings
Feb 19, 2026EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.16
Shares Outstanding57,434,740
10 Day Avg. Volume585,912
30 Day Avg. Volume1,169,804
Financial Highlights & Ratios
PEG Ratio150.23
Price to Book (P/B)10.31
Price to Sales (P/S)20.63
P/FCF Ratio-116.98
Enterprise Value/Market Cap0.73
Enterprise Value/Revenue9.60
Enterprise Value/Gross Profit12.49
Enterprise Value/Ebitda-116.09
Forecast
1Y Price Target
$118.10Price Target Upside8.63% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Market OpportunityKeratoconus impacts about 600,000 people annually, representing a significant market opportunity for GKOS estimated at approximately $3 billion.
Product AdoptionGiven increasing iDose adoption and Epioxa's upcoming launch, both of which could drive meaningful upside to revenue and earnings estimates, analyst reiterates Buy rating.
Revenue GrowthManagement raised its 2025 revenue guidance and provided 2026 revenue guidance that bracketed consensus.
Bears Say
Coverage ChallengesEpioxa will be a key long term growth driver for the company as it replaces Photrexa, but coverage density could take time given the high $78,500 WAC.
Market DisruptionGlaukos continues to expect material disruption in the fourth quarter as patients delay Photrexa procedures for the recently approved Epioxa procedure set to launch.
Regulatory ChallengesThe Nov 12 CAC meeting may continue to be an overhang for the stock shorter-term, given the market is not likely to treat the meeting with as optimistic a skew.
Glaukos News
GKOS FAQ
What was Glaukos Corp.’s price range in the past 12 months?
Glaukos Corp. lowest stock price was $73.16 and its highest was $163.71 in the past 12 months.
What is Glaukos Corp.’s market cap?
Glaukos Corp.’s market cap is $6.14B.
When is Glaukos Corp.’s upcoming earnings report date?
Glaukos Corp.’s upcoming earnings report date is Feb 19, 2026 which is in 69 days.
How were Glaukos Corp.’s earnings last quarter?
Glaukos Corp. released its earnings results on Oct 29, 2025. The company reported -$0.16 earnings per share for the quarter, beating the consensus estimate of -$0.261 by $0.101.
Is Glaukos Corp. overvalued?
According to Wall Street analysts Glaukos Corp.’s price is currently Undervalued.
Does Glaukos Corp. pay dividends?
Glaukos Corp. does not currently pay dividends.
What is Glaukos Corp.’s EPS estimate?
Glaukos Corp.’s EPS estimate is -0.21.
How many shares outstanding does Glaukos Corp. have?
Glaukos Corp. has 57,434,740 shares outstanding.
What happened to Glaukos Corp.’s price movement after its last earnings report?
Glaukos Corp. reported an EPS of -$0.16 in its last earnings report, beating expectations of -$0.261. Following the earnings report the stock price went up 13.893%.
Which hedge fund is a major shareholder of Glaukos Corp.?
Currently, no hedge funds are holding shares in GKOS
Glaukos Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$118.10 (8.63% Upside)
$118.10 (8.63% Upside)
Blogger Sentiment
Bullish
GKOS Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 314.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 6.6%
Last 30 Days ▼ 6.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-20.28%
12-Months-Change
Fundamentals
Return on Equity
-12.19%
Trailing 12-Months
Asset Growth
7.86%
Trailing 12-Months
Company Description
Glaukos Corp.
Glaukos Corporation (GKOS) is a medical technology company focused on the development and commercialization of innovative therapeutics for the treatment of glaucoma, a leading cause of blindness worldwide. The company operates primarily in the ophthalmic sector, offering a range of products designed to improve patient outcomes and reduce the burden of disease. Glaukos is best known for its micro-invasive glaucoma surgery (MIGS) products, which include the iStent and iStent inject systems, aimed at lowering intraocular pressure in patients with glaucoma.
GKOS Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Glaukos showcased strong financial performance with record sales and significant product approvals, particularly the FDA approval of Epioxa. However, the company faces challenges with transitioning its Corneal Health franchise and establishing market access for new products.View all GKOS earnings summariesGKOS Stock 12 Month Forecast
Average Price Target
$118.10
▲(8.63% Upside)
Technical Analysis
Integer Holdings
―
Ufp Technologies
―
Tandem Diabetes Care
―
LivaNova
―
Irhythm Technologies
―
Ownership Overview
3.71% Insiders
37.18% Mutual Funds
27.42% Other Institutional Investors
8.40% Public Companies and
Individual Investors